Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...

Before joining Gilead, Berger was previously the chief medical officer and global head of development at Sanofi, focusing on development science, strategy ... and Merdad played a fundamental role in ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

Twinning this cutting-edge cell therapy science with the expertise of Gilead in HIV and hepatitis C therapeutics, plus its massive marketing success, should ensure major success for the company.

At Stanford, Feinberg, Pande, and one group of colleagues presented the PotentialNet family of graph convolutions in a 2018 paper in ACS Central Science ... to the success that Genesis has ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

In a typical case of ownership pass-the-parcel, Cytopia was acquired by Canada’s YM Biosciences and the drug then was in the ...

Lenacapavir for Alzheimer’s, an orca attacking a shark, and a moon landing are set to mark key scientific and technological ...

Gilead’s CAR-T cancer ... muscle to make Yescarta a success: this is not a foregone conclusion when the economic model behind CAR-Ts is as novel as its science. Join the conversation, on Tuesday ...

The findings come as debates intensify around the H-1B visa programme, a key route for bringing skilled foreign professionals ...

A Gilead representative received a standing ovation at AIDS24 ... Scholar Rock’s spinal muscular atrophy (SMA) Phase III ...